News
LEO Pharma Presents Late-Breaking Results from Phase 2a Mechanism of Action Trial of Temtokibart + Dupilumab in Moderate-to-Severe Atopic Dermatitis ...
(RTTNews) - CytoDyn Inc. (CYDY.OB), a biotechnology company, Tuesday announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback